Kymera Therapeutics (NASDAQ:KYMR) Director Bruce Booth Sells 678 Shares

by · The Cerbat Gem

Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) Director Bruce Booth sold 678 shares of Kymera Therapeutics stock in a transaction that occurred on Friday, December 12th. The stock was sold at an average price of $91.04, for a total transaction of $61,725.12. Following the completion of the transaction, the director owned 685,393 shares in the company, valued at approximately $62,398,178.72. This trade represents a 0.10% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Bruce Booth also recently made the following trade(s):

  • On Thursday, December 11th, Bruce Booth sold 6,101 shares of Kymera Therapeutics stock. The stock was sold at an average price of $91.23, for a total value of $556,594.23.
  • On Wednesday, December 10th, Bruce Booth sold 229,809 shares of Kymera Therapeutics stock. The shares were sold at an average price of $91.73, for a total value of $21,080,379.57.

Kymera Therapeutics Stock Performance

Shares of KYMR stock traded up $1.87 during trading on Friday, hitting $89.68. 1,863,753 shares of the company were exchanged, compared to its average volume of 801,466. Kymera Therapeutics, Inc. has a twelve month low of $19.44 and a twelve month high of $103.00. The business’s 50-day simple moving average is $64.14 and its 200 day simple moving average is $51.43. The firm has a market capitalization of $6.45 billion, a price-to-earnings ratio of -24.98 and a beta of 2.28.

Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) last posted its earnings results on Tuesday, November 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.19). The business had revenue of $2.76 million during the quarter, compared to analyst estimates of $23.15 million. Kymera Therapeutics had a negative net margin of 674.81% and a negative return on equity of 32.92%. On average, equities analysts forecast that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

KYMR has been the subject of several recent research reports. Guggenheim started coverage on Kymera Therapeutics in a report on Monday, November 3rd. They issued a “buy” rating and a $90.00 price target for the company. UBS Group upgraded shares of Kymera Therapeutics to a “strong-buy” rating in a research report on Thursday, December 4th. Oppenheimer boosted their price target on shares of Kymera Therapeutics from $67.00 to $120.00 and gave the company an “outperform” rating in a research report on Tuesday. Truist Financial lifted their price target on Kymera Therapeutics from $80.00 to $116.00 and gave the company a “buy” rating in a report on Tuesday. Finally, BTIG Research set a $138.00 price objective on Kymera Therapeutics in a research report on Monday. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $112.80.

Check Out Our Latest Research Report on KYMR

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. CIBC Bancorp USA Inc. bought a new stake in shares of Kymera Therapeutics during the 3rd quarter worth approximately $304,000. Dark Forest Capital Management LP grew its position in Kymera Therapeutics by 19.7% during the 3rd quarter. Dark Forest Capital Management LP now owns 31,052 shares of the company’s stock worth $1,758,000 after acquiring an additional 5,102 shares during the last quarter. Alyeska Investment Group L.P. boosted its position in Kymera Therapeutics by 1,130.2% during the 3rd quarter. Alyeska Investment Group L.P. now owns 615,091 shares of the company’s stock worth $34,814,000 after buying an additional 565,091 shares during the period. Verition Fund Management LLC grew its stake in shares of Kymera Therapeutics by 270.9% in the third quarter. Verition Fund Management LLC now owns 31,471 shares of the company’s stock worth $1,781,000 after purchasing an additional 22,987 shares during the last quarter. Finally, Polar Capital Holdings Plc grew its position in shares of Kymera Therapeutics by 58.8% in the 3rd quarter. Polar Capital Holdings Plc now owns 397,041 shares of the company’s stock valued at $22,473,000 after buying an additional 147,041 shares during the last quarter.

About Kymera Therapeutics

(Get Free Report)

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.

See Also